Fossum B, Breivik J, Meling G I, Gedde-Dahl T, Hansen T, Knutsen I, Rognum T O, Thorsby E, Gaudernack G
Institute of Transplantation Immunology, National Hospital, University of Oslo, Norway.
Int J Cancer. 1994 Aug 15;58(4):506-11. doi: 10.1002/ijc.2910580409.
We have characterized and described in detail 2 CD4+ T-lymphocyte clones (TLC) from a colonic cancer patient. These TLC specifically recognize a K-ras-derived peptide carrying the 13Asp mutation commonly found in adenocarcinomas of the colon. The TLC were independently derived, as they carried 2 different T-cell receptors. The TLC recognized partly overlapping epitopes within the 13Asp peptide, presented by HLA-DQ7 molecules, suggesting that this molecule might confer some protective immunity against the mutation. On the basis of analysis of 251 colonic carcinomas, the presence of HLA-DQ7 did not seem to protect against the establishment of carcinomas carrying the 13Asp mutation, since the frequency of the DQ7 haplotype was not decreased among patients having this mutation. A modifying effect of DQ7 on the development of carcinomas with a 13Asp mutation was, however, observed, resulting in fewer tumours reaching advanced Dukes stages when DQ7 was present.
我们已对一名结肠癌患者的2个CD4 + T淋巴细胞克隆(TLC)进行了详细的特征描述。这些TLC特异性识别一种携带13Asp突变的K-ras衍生肽,该突变在结肠癌腺癌中常见。这些TLC是独立衍生的,因为它们携带2种不同的T细胞受体。TLC识别由HLA-DQ7分子呈递的13Asp肽内部分重叠的表位,这表明该分子可能赋予针对该突变的某种保护性免疫。基于对251例结肠癌的分析,HLA-DQ7的存在似乎并不能预防携带13Asp突变的癌的发生,因为在有此突变的患者中DQ7单倍型的频率并未降低。然而,观察到DQ7对具有13Asp突变的癌的发展有修饰作用,当存在DQ7时,进展到晚期杜克分期的肿瘤较少。